Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1822, Issue 2, 2012, Pages 130-138

  Cenini, Giovanna ^a   Dowling, Amy L S ^b   Beckett, Tina L ^b   Barone, Eugenio ^a,c   Mancuso, Cesare ^c   Murphy, Michael Paul ^b   LeVine, Harry ^b   Lott, Ira T ^d   Schmitt, Frederick A ^b   Butterfield, D Allan ^a   Head, Elizabeth ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c CATHOLIC UNIVERSITY   (Italy)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

3 Nitrotyrosine; 4 Hydroxy 2 nonenal; Alzheimer disease; Oligomer; Protein carbonyl; Trisomy 21

Indexed keywords

3 NITROTYROSINE; 4 HYDROXYNONENAL; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; OLIGOMER;

ADULT; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DOWN SYNDROME; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRONTAL CORTEX; GENOTYPE; HUMAN; HUMAN TISSUE; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; NITROSATIVE STRESS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CARBONYLATION; PROTEIN MODIFICATION;

ADOLESCENT; ADULT; AGE FACTORS; ALDEHYDES; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; DOWN SYNDROME; FEMALE; FRONTAL LOBE; HUMANS; MALE; MIDDLE AGED; NITROSATION; OXIDATION-REDUCTION; OXIDATIVE STRESS; SUPEROXIDE DISMUTASE; TYROSINE;

EID: 83055187877     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.10.001     Document Type: Article

References (82)

1. Aksenov M.Y., Aksenova M.V., Markesbery W.R., Butterfield D.A. Amyloid beta-peptide (1-40)-mediated oxidative stress in cultured hippocampal neurons. Protein carbonyl formation, CK BB expression, and the level of Cu, Zn, and Mn SOD mRNA. J. Mol. Neurosci.: MN 1998, 10:181-192.
2. Aksenov M.Y., Aksenova M.V., Butterfield D.A., Geddes J.W., Markesbery W.R. Protein oxidation in the brain in Alzheimer's disease. Neuroscience 2001, 103:373-383.
3. Azizeh B.Y., Head E., Ibrahim M.A., Torp R., Tenner A.J., Kim R.C., Lott I.T., Cotman C.W. Molecular dating of senile plaques in the brains of individuals with Down syndrome and in aged dogs. Exp. Neurol. 2000, 163:111-122.
4. Ball M.J., Nuttall K. Neurofibrillary tangles, granulovacuolar degeneration, and neuron loss in Down syndrome: quantitative comparison with Alzheimer dementia. Ann. Neurol. 1980, 7:462-465.
5. Beckett T.L., Niedowicz D.M., Studzinski C.M., Weidner A.M., Webb R.L., Holler C.J., Ahmed R.R., LeVine H., Murphy M.P. Effects of nonsteroidal anti-inflammatory drugs on amyloid-beta pathology in mouse skeletal muscle. Neurobiol. Dis. 2010, 39:449-456.
6. Behl C., Davis J.B., Lesley R., Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 1994, 77:817-827.
7. Bradley M.A., Xiong-Fister S., Markesbery W.R., Lovell M.A. Elevated 4-hydroxyhexenal in Alzheimer's disease (AD) progression. Neurobiol. Aging 2010, 10.1610/j.neurobiolaging.2010.08.016.
8. Brooksbank B.W., Martinez M., Balazs R. Altered composition of polyunsaturated fatty acyl groups in phosphoglycerides of Down's syndrome fetal brain. J. Neurochem. 1985, 44:869-874.
9. Busciglio J., Andersen J.K., Schipper H.M., Gilad G.M., McCarty R., Marzatico F., Toussaint O. Stress, aging, and neurodegenerative disorders. Molecular mechanisms. Ann. N. Y. Acad. Sci. 1998, 851:429-443.
10. Busciglio J., Pelsman A., Wong C., Pigino G., Yuan M., Mori H., Yankner B.A. Altered metabolism of the amyloid β precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron 2002, 33:677-688.
11. Busciglio J., Yankner B.A. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature 1995, 378:776-779.
12. Bush A., Beail N. Risk factors for dementia in people with down syndrome: issues in assessment and diagnosis. Am. J. Ment. Retard. 2004, 109:83-97.
13. Butterfield D.A., Bader Lange M.L., Sultana R. Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease. Biochim. Biophys. Acta 2010, 1801:924-929.
14. Butterfield D.A., Reed T., Sultana R. Roles of 3-nitrotyrosine- and 4-hydroxynonenal-modified brain proteins in the progression and pathogenesis of Alzheimer's disease. Free. Radic. Res. 2010, 45:59-72.
15. Butterfield D.A., Drake J., Pocernich C., Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol. Med. 2001, 7:548-554.
16. Butterfield D.A., Reed T.T., Perluigi M., De Marco C., Coccia R., Keller J.N., Markesbery W.R., Sultana R. Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer's disease. Brain Res. 2007, 1148:243-248.
17. Butterfield D.A., Galvan V., Lange M.B., Tang H., Sowell R.A., Spilman P., Fombonne J., Gorostiza O., Zhang J., Sultana R., Bredesen D.E. In vivo oxidative stress in brain of Alzheimer disease transgenic mice: requirement for methionine 35 in amyloid beta-peptide of APP. Free Radic. Biol. Med. 2010, 48:136-144.
18. Cataldo A.M., Petanceska S., Terio N.B., Peterhoff C.M., Durham R., Mercken M., Mehta P.D., Buxbaum J., Haroutunian V., Nixon R.A. Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome. Neurobiol. Aging 2004, 25:1263-1272.
19. Cataldo A.M., Peterhoff C.M., Troncoso J.C., Gomez-Isla T., Hyman B.T., Nixon R.A. Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am. J. Pathol. 2000, 157:277-286.
20. CDC Improved national prevalence estimates for 18 selected major birth defects-United States, 1999-2001 2006.
21. de Haan J.B., Wolvetang E.J., Cristiano F., Iannello R., Bladier C., Kelner M.J., Kola I. Reactive oxygen species and their contribution to pathology in Down syndrome. Adv. Pharmacol. 1997, 38:379-402.
22. Deshpande A., Mina E., Glabe C., Busciglio J. Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J. Neurosci. 2006, 26:6011-6018.
23. Giuffrida M.L., Caraci F., Pignataro B., Cataldo S., De Bona P., Bruno V., Molinaro G., Pappalardo G., Messina A., Palmigiano A., Garozzo D., Nicoletti F., Rizzarelli E., Copani A. Beta-amyloid monomers are neuroprotective. J. Neurosci.: Off. J. Soc. Neurosci. 2009, 29:10582-10587.
24. Groner Y., Elroy-Stein O., Avraham K.B., Yarom R., Schickler M., Knobler H., Rotman G. Down syndrome clinical symptoms are manifested in transfected cells and transgenic mice overexpressing the human Cu/Zn-superoxide dismutase gene. J. Physiol. (Paris) 1990, 84:53-77.
25. Groner Y., Elroy-Stein O., Avraham K.B., Schickler M., Knobler H., Minc-Golomb D., Bar-Peled O., Yarom R., Rotshenker S. Cell damage by excess CuZnSOD and Down's syndrome. Biomed. Pharmacother. 1994, 48:231-240.
26. Harris M.E., Hensley K., Butterfield D.A., Leedle R.A., Carney J.M. Direct evidence of oxidative injury produced by the Alzheimer's beta-amyloid peptide (1-40) in cultured hippocampal neurons. Exp. Neurol. 1995, 131:193-202.
27. Head E., Garzon-Rodriguez W., Johnson J.K., Lott I.T., Cotman C.W., Glabe C. Oxidation of Abeta and plaque biogenesis in Alzheimer's disease and Down syndrome. Neurobiol. Dis. 2001, 8:792-806.
28. Hensley K., Carney J.M., Mattson M.P., Aksenova M., Harris M., Wu J.F., Floyd R.A., Butterfield D.A. A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:3270-3274.
29. Hensley K., Hall N., Subramaniam R., Cole P., Harris M., Aksenov M., Aksenova M., Gabbita S.P., Wu J.F., Carney J.M., et al. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J. Neurochem. 1995, 65:2146-2156.
30. Hof P.R., Bouras C., Perl D.P., Sparks D.L., Mehta N., Morrison J.H. Age-related distribution of neuropathologic changes in the cerebral cortex of patients with Down's syndrome. Arch. Neurol. 1995, 52:379-391.
31. Huang X., Atwood C.S., Hartshorn M.A., Multhaup G., Goldstein L.E., Scarpa R.C., Cuajungco M.P., Gray D.N., Lim J., Moir R.D., Tanzi R.E., Bush A.I. The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 1999, 38:7609-7616.
32. Iannello R.C., Crack P.J., de Haan J.B., Kola I. Oxidative stress and neural dysfunction in Down syndrome. J. Neural Transm. 1999, 57:257-267.
33. Ill-Raga G., Ramos-Fernandez E., Guix F.X., Tajes M., Bosch-Morato M., Palomer E., Godoy J., Belmar S., Cerpa W., Simpkins J.W., Inestrosa Nc, Munoz F.J. Amyloid-beta peptide fibrils induce nitro-oxidative stress in neuronal cells. J. Alzheimer's Dis.: JAD 2010, 22:641-652.
34. Ishihara K., Amano K., Takaki E., Ebrahim A.S., Shimohata A., Shibazaki N., Inoue I., Takaki M., Ueda Y., Sago H., Epstein C.J., Yamakawa K. Increased lipid peroxidation in Down's syndrome mouse models. J. Neurochem. 2009, 110:1965-1976.
35. Jovanovic S.V., Clements D., MacLeod K. Biomarkers of oxidative stress are significantly elevated in Down syndrome. Free Radic. Biol. Med. 1998, 25:1044-1048.
36. Karlsen A.S., Pakkenberg B. Total numbers of neurons and glial cells in cortex and basal ganglia of aged brains with Down syndrome-a stereological study. Cereb. Cortex 2011, 21:2519-2524.
37. Kedziora J., Bartosz G. Down's syndrome: a pathology involving the lack of balance of reactive oxygen species. Free Radic. Biol. Med. 1988, 4:317-330.
38. Knauer M.F., Soreghan B., Burdick D., Kosmoski J., Glabe C.G. Intracellular accumulation and resistance to degradation of the Alzheimer amyloid A4/beta protein. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:7437-7441.
39. Lai F., Williams M.D. A prospective study of Alzheimer disease in Down syndrome. Arch. Neurol. 1989, 46:849-853.
40. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., Klein W.L. Diffusable, nonfibrillar ligands derived from Ab1-42 are potent central nervous system neurotoxins. PNAS 1998, 95:6448-6453.
41. Lee M., Hyun D., Jenner P., Halliwell B. Effect of overexpression of wild-type and mutant Cu/Zn-superoxide dismutases on oxidative damage and antioxidant defences: relevance to Down's syndrome and familial amyotrophic lateral sclerosis. J. Neurochem. 2001, 76:957-965.
42. Lejeune J., Gautier M., Turpin R. Etude des chromosomes somatiques de neuf enfants mongoliens. C. R. Hebd. Seances Acad. Sci. 1959, 248:1721-1722.
43. Lemere C.A., Blusztajn J.K., Yamaguchi H., Wisniewski T., Saido T.C., Selkoe D.J. Sequence of deposition of heterogeneous amyloid beta-peptides and APOE in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol. Dis. 1996, 3:16-32.
44. Lesne S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., Ashe K.H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440:352-357.
45. Leverenz J.B., Raskind M.A. Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp. Neurol. 1998, 150:296-304.
46. Li S., Hong S., Shepardson N.E., Walsh D.M., Shankar G.M., Selkoe D. Soluble oligomers of amyloid beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 2009, 62:788-801.
47. Lott I.T. Down's syndrome, aging, and Alzheimer's disease: a clinical review. Ann. N. Y. Acad. Sci. 1982, 396:15-27.
48. Lott I.T., Head E. Down syndrome and Alzheimer's disease: a link between development and aging. Ment. Retard. Dev. Disabil. Res. Rev. 2001, 7:172-178.
49. Lott I.T., Head E. Alzheimer disease and Down syndrome: factors in pathogenesis. Neurobiol. Aging 2005, 26:383-389.
50. Lott I.T., Head E., Doran E., Busciglio J. Beta-amyloid, oxidative stress and Down syndrome. Curr. Alzheimer Res. 2006, 3:521-528.
51. Manczak M., Calkins M.J., Reddy P.H. Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage. Hum. Mol. Genet. 2011, 20:2495-2509.
52. Mann D.M., Marcyniuk B., Yates P.O., Neary D., Snowden J.S. The progression of the pathological changes of Alzheimer's disease in frontal and temporal neocortex examined both at biopsy and at autopsy. Neuropathol. Appl. Neurobiol. 1988, 14:177-195.
53. Mann D.M.A., Esiri M.M. The pattern of acquisition of plaques and tangles in the brains of patients under 50years of age with Down's syndrome. J. Neurol. Sci. 1989, 89:169-179.
54. Markesbery W.R. Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med. 1997, 23:134-147.
55. Mazur-Kolecka B., Golabek A., Nowicki K., Flory M., Frackowiak J. Amyloid-beta impairs development of neuronal progenitor cells by oxidative mechanisms. Neurobiol. Aging 2006, 27:1181-1192.
56. Nistor M., Don M., Parekh M., Sarsoza F., Goodus M., Lopez G.E., Kawas C., Leverenz J., Doran E., Lott I.T., Hill M., Head E. Alpha- and beta-secretase activity as a function of age and beta-amyloid in Down syndrome and normal brain. Neurobiol. Aging 2007, 28:1493-1506.
57. Nunomura A., Perry G., Hirai K., Aliev G., Takeda A., Chiba S., Smith M.A. Neuronal RNA oxidation in Alzheimer's disease and Down's syndrome. Annals NYAS 1999, 893:362-364.
58. Nunomura A., Perry G., Pappolla M., Friedland R.P., Hirai K., Chiba S., Smith M.A. Neuronal oxidative stress precedes amyloid-β deposition in Down syndrome. J. Neuropathol. Exp. Neurol. 2000, 59:1011-1017.
59. Odetti P., Angelini G., Dapino D., Zaccheo D., Garibaldi S., Dagna-Bricarelli F., Piombo G., Perry G., Smith M., Traverso N., Tabaton M. Early glycoxidation damage in brains from Down's syndrome. Biochem. Biophys. Res. Commun. 1998, 243:849-851.
60. Perluigi M., Di Domenico F., Fiorini A., Cocciolo A., Giorgi A., Foppoli C., Butterfield D.A., Giorlandino M., Giorlandino C., Schinina M.E., Coccia R. Oxidative stress occurs early in Down syndrome pregnancy: a redox proteomics analysis of amniotic fluid. Proteomics Clin. Appl. 2011, 5:167-178.
61. Pike C.J., Walencewicz A.J., Glabe C.G., Cotman C.W. In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 1991, 563:311-314.
62. Pratico D., Uryu K., Leight S., Trojanoswki J.Q., Lee V.M. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J. Neurosci. 2001, 21:4183-4187.
63. Pratico D., Iuliano L., Amerio G., Tang L.X., Rokach J., Sabatino G., Violi F. Down's syndrome is associated with increased 8,12-iso-iPF2alpha-VI levels: evidence for enhanced lipid peroxidation in vivo. Ann. Neurol. 2000, 48:795-798.
64. Reddy P.H. Amyloid precursor protein-mediated free radicals and oxidative damage: implications for the development and progression of Alzheimer's disease. J. Neurochem. 2006, 96:1-13.
65. Riahi Y., Cohen G., Shamni O., Sasson S. Signaling and cytotoxic functions of 4-hydroxyalkenals. Am. J. Physiol. Endocrinol. Metab. 2010, 299:E879-886.
66. Roizen N.J., Patterson D. Down's syndrome. Lancet 2003, 361:1281-1289.
67. Sarsoza F., Saing T., Kayed R., Dahlin R., Dick M., Broadwater-Hollifield C., Mobley S., Lott I., Doran E., Gillen D., Anderson-Bergman C., Cribbs D.H., Glabe C., Head E. A fibril-specific, conformation-dependent antibody recognizes a subset of Abeta plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain. Acta Neuropathol. 2009, 118:505-517.
68. Schuchmann S., Heinemann U. Increased mitochondrial superoxide generation in neurons from trisomy 16 mice: a model of Down's syndrome. Free Radic. Biol. Med. 2000, 28:235-250.
69. Schupf N., Patel B., Pang D., Zigman W.B., Silverman W., Mehta P.D., Mayeux R. Elevated plasma beta-amyloid peptide Abeta (42) levels, incident dementia, and mortality in Down syndrome. Arch. Neurol. 2007, 64:1007-1013.
70. Schupf N., Zigman W.B., Tang M.X., Pang D., Mayeux R., Mehta P., Silverman W. Change in plasma Aβ peptides and onset of dementia in adults with Down syndrome. Neurology 2010, 75:1639-1644.
71. Schupf N., Sergievsky G.H. Genetic and host factors for dementia in Down's syndrome. Br. J. Psychiatry 2002, 180:405-410.
72. Selkoe D.J. Normal and abnormal biology of the beta-amyloid precursor protein. Annu. Rev. Neurosci. 1994, 17:489-517.
73. Shoji M., Golde T.E., Ghiso J., Cheung T.T., Estus S., Shaffer L.M., Cai X.D., McKay D.M., Tintner R., Frangione B., et al. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 1992, 258:126-129.
74. Smith M.A., Perry G., Richey P.L., Sayre L.M., Anderson V.E., Beal M.F., Kowall N. Oxidative damage in Alzheimer's. Nature 1996, 382:120-121.
75. Tyrrell J., Cosgrave M., McCarron M., McPherson J., Calvert J., Kelly A., McLaughlin M., Gill M., Lawlor B.A. Dementia in people with Down's syndrome. Int. J. Geriatr. Psychiatry 2001, 16:1168-1174.
76. Uchida K. 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog. Lipid Res. 2003, 42:318-343.
77. Varadarajan S., Yatin S., Aksenova M., Butterfield D.A. Review: Alzheimer's amyloid β-peptide-associated free radical oxidative stress and neurotoxicity. J. Struct. Biol. 2000, 130:184-208.
78. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539.
79. Wang D.-S., Iwata N., Hama E., Saido T.C., Dickson D.W. Oxidized neprilysin in aging and Alzheimer's disease brains. Biochem. Biophys. Res. Commun. 2003, 310:236-241.
80. Weidemann A., Konig G., Bunke D., Fischer P., Salbaum J.M., Masters C.L., Beyreuther K. Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. Cell 1989, 57:115-126.
81. Wisniewski K., Wisniewski H., Wen G. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann. Neurol. 1985, 17:278-282.
82. Yatin S.M., Varadarajan S., Link C.D., Butterfield D.A. In vitro and in vivo oxidative stress associated with Alzheimer's amyloid beta-peptide (1-42). Neurobiol. Aging 1999, 20:325-330. (discussion 339-342).